Alexion Announces Positive Top-Line Results Showing Successful Phase 3 Clinical Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) | Business Wire

Alexion Announces Positive Top-Line Results Showing Successful Phase 3 Clinical Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) | Business Wire: Alexion Announces Positive Top-Line Results Showing Successful Phase 3 Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Patients with PNH